WASHINGTON (MedPage Today) — A report by the Centers for Medicare and Medicaid Services actuary said the Senate’s healthcare reform bill would not save enough money on Medicare to finance healthcare for more Americans who aren’t covered by insurance now.
No Comments »
Filed under: General Health News
WASHINGTON –The FDA has contacted healthcare professionals and patients to warn of a growing concern over rare but potentially fatal complications from negative pressure wound therapy.
No Comments »
Filed under: General Health News
WASHINGTON (MedPage Today) — The notion of a public health insurance plan appears to be evaporating from the Senate’s healthcare reform bill, replaced in part with an expansion of Medicare — an idea that met with resistance from doctor and hospital associations.
No Comments »
Filed under: General Health News
WASHINGTON –The FDA has contacted healthcare professionals and patients to warn of a growing concern over rare but potentially fatal complications from negative pressure wound therapy.
No Comments »
Filed under: Pharmacy News
WASHINGTON (MedPage Today) — The FDA approved the first platelet additive solution (InterSol) for replacing a portion of plasma to store blood platelets for up to five days.
No Comments »
Filed under: Pharmacy News
Welichem today announced that the Company has begun to enroll patients in a Phase IIb clinical trial with its lead candidate, WBI-1001. The Phase IIb clinical trial is a double-blinded, placebo-controlled, 12-week-treatment study.
No Comments »
Filed under: Pharmacy News
iCo Therapeutics Inc. - iCo Therapeutics (”iCo”) is pleased to announce that its Phase 1 clinical trial of iCo-007, having enrolled all patients in four cohorts of increasing concentration (110ug, 350ug, 700ug, 1000ug), has to date demonstrated a positive safety profile.
No Comments »
Filed under: Pharmacy News
Ambit Biosciences Corporation announced today the enrollment and dosing at the University of Texas M. D. Anderson Cancer Center of the first patient in the ACE (AC220 Monotherapy Efficacy) Phase 2 pivotal trial in patients with relapsed or refractory acute myeloid leukemia (AML).
No Comments »
Filed under: Pharmacy News
Spectrum Pharmaceuticals, Inc., a commercial stage biotechnology company with a primary focus in oncology, today announced that clinical data on ZEVALIN (ibritumomab tiuxetan) was presented at the 51st Annual Meeting of the American Society of Hematology (ASH), which was held December 5-8, 2009 at the Ernest N. Morial Convention Center in New Orleans, Louisiana.
No Comments »
Filed under: Pharmacy News
Seattle Genetics, Inc. today reported that it has been notified by Genentech, a wholly owned member of the Roche Group, that Genentech has elected to terminate the companies’ collaboration agreement for dacetuzumab (SGN-40). Dacetuzumab is a monoclonal antibody targeting CD40 that has been investigated in clinical trials for non-Hodgkin lymphoma and multiple myeloma.
No Comments »
Filed under: Pharmacy News
